Back    Zoom +    Zoom -
Sanofi Acquires Dynavax (DVAX.US) for US$2.2B
Recommend
1
Positive
2
Negative
0
Sanofi agreed to acquire Dynavax Technologies (DVAX.US) for approximately US$2.2 billion to expand its vaccine business. Dynavax's vaccine portfolio includes a hepatitis B vaccine and an experimental shingles vaccine.

Sanofi will purchase California-based Dynavax for US$15.5 per share in cash, representing a 39% premium over Tuesday's (23rd) closing price.

Related NewsInitial Jobless Claims for Dec/20 in United States is 214K, lower than the previous value of 224K. The forecast was 223K.
Sanofi expects that the deal will not influence this year's financial guidance and believes it can be completed in the first quarter of next year.
AASTOCKS Financial News
Website: www.aastocks.com